TABLE 3.
Differences in clinical characteristics and management between central‐ and peripheral‐type SCLC patients
| Total, n = 67 | Central, n = 27 (%) | Peripheral, n = 40 (%) | ||||
|---|---|---|---|---|---|---|
| First treatment | ||||||
| Surgery | 1 (3.7) | 9 (22.5) | ||||
| Radiotherapy | 0 (0) | 1 (2.5) | ||||
| Chemo‐radiotherapy | 6 (22.2) | 5 (12.5) | ||||
| Chemotherapy | 19 (70.4) | 20 (50.0) | ||||
| None | 1 (3.7) | 5 (12.5) | ||||
| ED, n = 39 | Central, n = 17 (%) | Peripheral, n = 22 (%) | OR (95% CI) | p value | ||
| Emphysema | 18.67 (2.48–214.7) | 0.002 | ||||
| Yes | 9 (52.9) | 15 (68.2) | ||||
| No | 8 (47.1) | 7 (31.8) | ||||
| ILD | 2.0 (0.531–7.48) | 0.307 | ||||
| Yes | 5 (29.4) | 10 (45.6) | ||||
| No | 12 (70.6) | 12 (55.4) | ||||
| Number of treatment lines | 1.905 (0.154–1.986) | 0.332 | ||||
| 0 or 1 | 9 (52.9) | 15 (68.2) | ||||
| >2 | 8 (47.1) | 7 (31.8) | ||||
| Drug‐induced pneumonia or exacerbation of ILD | 3.556 (0.472–45.9) | 0.255 | ||||
| Yes | 1 (5.9) | 4 (18.2) | ||||
| No | 16 (94.1) | 18 (81.8) |
Abbreviations: CI, confidence interval; ED, extensive disease; ILD, interstitial lung disease; OR, odds ratio; SCLC, small‐cell lung cancer.